CRISPR Therapeutics Proposes New Appointment to the Board of Directors

ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company’s annual general meeting to be held this year.

“We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. “His in-depth experience in successfully accelerating innovation and advancing drug candidates across a breadth of modalities will be an invaluable asset to CRISPR Therapeutics as we continue to advance our platform and pipeline to develop transformative medicines for patients suffering from serious diseases.”

“CRISPR Therapeutics is leading the next wave of innovation in gene editing and has the potential to transform the treatment paradigm of medicine,” said Christian Rommel, Ph.D., Executive Vice President, Global Head of Research & Development and Member of the Executive Committee of Bayer Pharmaceuticals, Inc. "I look forward to working with the Board of Directors and management team to help guide the company's future growth, and to deliver meaningful impact to patients."

Dr. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals, Inc. He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED). Before that, Dr. Rommel worked at Amgen where he held roles such as Vice President of External Research and Development and Vice President, Research Oncology. Previously, he served as Chief Scientific Officer of Intellikine from its inception to acquisition by Takeda. His prior positions also include leadership as well as scientist roles at Merck Serono and Regeneron. Dr. Rommel received his Ph.D. in molecular oncology from the Max Planck Institute in Berlin, Germany and the Institute of Medical Virology at the University of Zurich, Switzerland. He is also a lecturer of biotechnology at the ETH Zurich, Switzerland. He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor of 18 patents.